FdaApplication
NDA 214377
Identifiers
- fda_app_no: NDA214377
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME LLC |
| application_type | NDA |
| approval_date | 2021-01-19 |
Revenue by product
VERQUVO
| Period | Revenue |
|---|---|
| Q2 2026 | $9.0M |
| Q1 2026 | $9.0M |
| Q4 2025 | $15.0M |
| Q3 2025 | $12.0M |
| Q2 2025 | $11.0M |
| Q1 2025 | $9.0M |
| Q4 2024 | $12.0M |
| Q3 2024 | $11.0M |
| Q2 2024 | $9.0M |
| Q1 2024 | $5.0M |
| Q4 2023 | $12.0M |
| Q3 2023 | $8.0M |
| Q2 2023 | $9.0M |
| Q1 2023 | $7.0M |
| Q4 2022 | $7.0M |
| Q3 2022 | $6.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VERQUVO | VERICIGUAT | 10MG | TABLET;ORAL |
| VERQUVO | VERICIGUAT | 2.5MG | TABLET;ORAL |
| VERQUVO | VERICIGUAT | 5MG | TABLET;ORAL |
3 products